Article
The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Cancer medicine - 1 Oct 2022
Chen Hanxiao, Huang Dingzhi, Lin Gen, Yang Xue, Zhuo Minglei, Chi Yujia, Zhai Xiaoyu, Jia Bo, Wang Jingjing, Wang Yuyan, Li Jianjie, An Tongtong, Wu Meina, Wang Ziping, Zhao Jun
Abstract excerpt
OBJECTIVE: Kirsten rat sarcoma viral oncogene homolog (KRAS) is an important driver gene of non-small cell lung cancer (NSCLC). Despite a rapid progress achieved in the targeted therapy, chemotherapy remains the standard treatment option for patients with KRAS-mutant NSCLC. This study aimed to assess real-world data of Chinese patients with KRAS-mutant NSCLC undergoing chemotherapy and/or immunotherapy. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
